Plasma cell–directed therapy for rituximab-refractory PLA2R+ membranous nephropathy
Nephrology Dialysis Transplantation · 30.11.2023 · 38 (12) · 2851-2853
DOI: 10.1093/ndt/gfad135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 03.07.2023. Verfasst von Sofiane Salhi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organ Transplantation, National Reference Centre for Rare Kidney Diseases - SORARE, University Hospital of Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: University Hospital of Toulouse, Institutional Axis of Research TImE.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Organ Transplantation, National Reference Centre for Rare Kidney Diseases - SORARE, University Hospital of Toulouse, Toulouse, France.
- Laboratory of Immunology, University Hospital of Toulouse, Toulouse, France.
- University Paul Sabatier - Toulouse 3, Faculty of Medicine, Toulouse, France.
- INSERM UMR 1297, Institute of Metabolic and Cardiovascular Diseases, Team 'Kidney Diseases: biomarkers, prevention and treatment', Toulouse, France.
Förderung
- University Hospital of Toulouse
- Institutional Axis of Research TImE
Zitieren
APA
Salhi, S., Ribes, D., Fortenfant, F., & Faguer, S. (2023). Plasma cell–directed therapy for rituximab-refractory PLA2R+ membranous nephropathy. Nephrology Dialysis Transplantation, 38(12), 2851-2853. https://doi.org/10.1093/ndt/gfad135
Vancouver
Salhi S, Ribes D, Fortenfant F, Faguer S. Plasma cell–directed therapy for rituximab-refractory PLA2R+ membranous nephropathy. Nephrology Dialysis Transplantation. 2023;38(12):2851-2853. doi:10.1093/ndt/gfad135
BibTeX
@article{Salhi2023,
author = {Salhi, Sofiane and Ribes, David and Fortenfant, Françoise and Faguer, Stanislas},
title = {Plasma cell–directed therapy for rituximab-refractory PLA2R+ membranous nephropathy},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
volume = {38},
number = {12},
pages = {2851--2853},
doi = {10.1093/ndt/gfad135}
}
EUVIMED